Cereno Scientific to present preclinical data for drug candidate CS585, a novel IP receptor agonist, at the ESC Congress 2024
Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innovative treatments for common and rare cardiovascular disease, today announced that an abstract on the preclinical drug candidate, novel IP receptor agonist CS585 has been accepted and will be presented at the ESC Congress 2024, in London, August 31, 2024.The abstract titled “CS585, a novel prostacyclin receptor agonist, demonstrates sustained efficacy in vivo in the prevention of thrombosis”, was co-authored, and will be presented, by Michael Holinstat, Professor at the Department of Pharmacology, the